News

Nesina, a highly selective DPP-4 inhibitor for the treatment of type 2 diabetes, has received regulatory approval from the Japanese Ministry of Health, Labour and Welfare on April

Parabolic Drugs intends to add capacity at its plant in Derabassi and establish new facilities in Chachrauli and Panchkula, with a plan to use the latter for custom

According to Glucan and AGG Polycan is a clinically proved water soluble active compound which helps in maintaining good bone health and a healthy immune system. Polycan is

Patheon has posted a net income of $10.9m, compared to $0.5m for the prior year period. Operating income was $15m, compared to $13.4m for the prior year period.

According to the MMR, the patent is an asset relating to its vaccine trials and use of customized tumor cells to treat lymphoma patients. Over the past 12

The study is expected to be conducted in the Netherlands at four investigational sites and the company anticipates to evaluate total of 21 to 30 patients in the

The data was presented during a presentation at the European Hematology Association (EHA) meeting being held June 10-13, 2010 in Barcelona, Spain. According to Allos, out of 54

According to the Medidata, Balance allows study teams to reduce trial planning and implementation time, effort and costs and the number of subjects required to be enrolled. The

CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. CTI is in the process of preparing a